Extractables Studies on Single-Use Components in ADC Manufacturing

In this exclusive webinar, join Dr. Alfred Haglind, senior scientist and Mark Ayles, senior marketing manager, Cytiva, as they explain why antibody-drug conjugate (ADC) manufacturing is well suited to single-use technology due to small batch sizes and minimal operator exposure to toxins. Plus, explore why adding new components with more diverse materials into your processes means you will have to gather more extractables data.

The speakers will also share invaluable insights from Cytiva's recent study of extractables from single-use components used in ADC manufacturing. The study evaluated the compatibility of wetted materials and subcomponents with toxic solvents used in the process, the ReadyToProcess column housing, and the ÄKTA ready and ÄKTA readyflux™ flow kits, providing essential findings for optimizing ADC manufacturing processes.

Key learning objectives

• Discover the latest datafindings related to extractables and leachables (E&L) compatibility for multiple single-use components used in the conjugation of ADCs
• Understand E&L risks and ways to further mitigate the risks to improve regulatory compliance

Who should attend?

• MSAT, Quality, Process Development

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.